News | Cardiovascular Clinical Studies | September 08, 2022

FOURIER-OLE Trial Finds that Long-term Use of Evolocumab Further Reduced Cardiovascular Events

investigator Michelle O’Donoghue, MD, MPH, a senior investigator of the TIMI Study Group in the Division of Cardiovascular Medicine. Image courtesy of Michelle O'Donoghue/Brigham and Women's Hospital

investigator Michelle O’Donoghue, MD, MPH, a senior investigator of the TIMI Study Group in the Division of Cardiovascular Medicine. Image courtesy of Michelle O'Donoghue/Brigham and Women's Hospital


September 8, 2022 — A clinical trial led by investigators from Brigham and Women’s Hospital has found that the long-term use of the cholesterol lowering drug evolocumab was safe, well tolerated, and led to further reductions in the risk of cardiovascular events compared to shorter treatment. Findings from the trial, known as FOURIER open-label extension (OLE), sponsored by Amgen, were presented at a Hot Line session at ESC Congress 2022 by the study’s principal investigator Michelle O’Donoghue, MD, MPH, a senior investigator of the TIMI Study Group in the Division of Cardiovascular Medicine. More than 6,000 participants from the parent trial were enrolled in FOURIER-OLE. During the extension period of the trial, patients received open-label subcutaneous injections of the PCSK9 inhibitor evolocumab regardless of whether they were originally randomized to receive the drug or the placebo. Participants were followed for a median of five years and, therefore, some patients were treated with evolocumab for more than eight years over the course of the parent and extension phase. Those originally randomized to receive evolocumab had a 15 percent lower risk of cardiovascular death, myocardial infarction (MI), stroke, hospitalization for unstable angina or coronary revascularization; a 20 percent lower risk of cardiovascular death, MI or stroke; and a 23 percent lower risk of cardiovascular death during OLE compared to those who were originally randomized to receive the placebo.

“To date, most clinical trials of PCSK9 inhibitors like evolocumab have only looked at its impact over two to three years, but most patients will be on a lipid-lowering therapy for many years,” said O’Donoghue. “Our study has found that long-term use of evolocumab was safe and led to further reductions in cardiovascular events among those who were started on the drug earlier, providing further support for guidelines recommending lipid-lowering therapy with PCSK9 inhibitors.”

For more information: https://www.brighamandwomens.org/

Find more content from ESC22     

Related content:

Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease

Alirocumab Reduces Cardiovascular Events after Acute Coronary Syndrome


Related Content

News | ESC

September 1, 2022 — “At ESC Congress in Barcelona, we discussed the newest science in the light of our collective ...

Home September 01, 2022
Home
News | ESC

August 30, 2022 — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its latest ...

Home August 30, 2022
Home
News | ESC

August 30, 2022 — A pill containing aspirin and medications to lower lipids and blood pressure more effectively prevents ...

Home August 30, 2022
Home
News | ESC

August 30, 2022 — Abbott announced new late-breaking data that show its HeartMate 3 heart pump extends survival of ...

Home August 30, 2022
Home
News | ESC

August 29, 2022 — Amarin Corporation plc announced that new REDUCE-IT data show that VASCEPA/VAZKEPA (icosapent ethyl) ...

Home August 29, 2022
Home
News | ESC

Organizers of the European Society of Cardiology (ESC) Congress have released plans and announced 10 Hot Line Sessions ...

Home July 22, 2022
Home
News | ESC

June 1, 2022 — Eating low glycaemic index foods promotes a healthier body shape in patients with coronary artery disease ...

Home June 01, 2022
Home
News | ESC

May 9, 2022 — Heart failure presents differently in women and men – discover the latest evidence and its impact on ...

Home May 09, 2022
Home
News | ESC

March 31, 2022 — The annual congress of the European Heart Rhythm Association (EHRA), a branch of the ESC, will be held ...

Home March 31, 2022
Home
News | ESC

January 3, 2022 — The following is a list of the 2021 news stories from the European Society of Cardiology (ESC) ...

Home January 03, 2022
Home
Subscribe Now